Revue médicale de Liège
-
Revue médicale de Liège · Apr 2016
Case Reports[PERIOPERATIVE VISUAL LOSS AFTER SPINE SURGERY: A CASE REPORT].
Perioperative visual loss is a rare but devastating complication that may follow spine surgery in the prone position. So far, the incidence, mechanisms and risk factors have not been clearly established. Most commonly, the visual loss results from an ischemic optic neuropathy. ⋯ Upon recovery from anesthesia, the patient complained of total left blindness. This visual loss was, slowly and only partially, recovered after 72 hours. We discuss the most common causes of postoperative visual loss, the risk factors and preventive strategy.
-
Revue médicale de Liège · Apr 2016
Case Reports[POST-CAESAREAN ABDOMINAL WALL ENDOMETRIOSIS PREVENTION].
Abdominal wall endometriosis (AWE) is a rare type of endometriosis. Its pathophysiological pathways are still unknown. It generally occurs after surgical, mainly gynecological or obstetrical, interventions. ⋯ Each patient had a caesarean section. Their symptoms, however, occurred after various lengths of time and in different circumstances. We will more specifically discuss AWE secondary to cesarean sections, the diagnostic tools, treatment and prevention strategies.
-
With the introduction of the use of Laser assisted surgery, refractive eye surgery knows a very large success. Surgery of well being, it requires that an extensive information is delivered to the patient concerning the benefit and possible side-effects of the available treatments. This information process may reduce the frequency of negligence claims relating to Laser eye surgery.
-
Revue médicale de Liège · Jan 2016
Review[THE MALADAPTIVE BELIEFS OF PATIENTS WITH LOW BACK PAIN. A NARRATIVE REVIEW].
to summarize the knowledge regarding the maladaptive beliefs of patients with non-specific low back pain. ⋯ Misbeliefs are frequent in patient with low back pain. They do need to be looked for and corrected.
-
Revue médicale de Liège · Nov 2015
[EMPA-REG OUTCOME: Empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk].
EMPA-REG OUTCOME is an international, prospective, placebo-controlled clinical trial investigating the cardiovascular outcomes of empagliflozin, an inhibitor of sodium-glucose cotransporters type 2 (SGLT2), in patients with type 2 diabetes mellitus and known cardiovascular disease. The trial succeeded in reaching the primary objective of non-inferiority and, in addition, showed, after a median follow up of 3.1 years, a superiority of empagliflozin (10 or 25 mg/day) versus placebo as regards the primary composite cardiovascular endpoint (hasard ratio or HR = 0.86; 95% CI 0.74-0.99; P = 0.04), hospitalisations for heart failure (-35%), cardiovascular mortality (-38%) and all-cause mortality (-32%, each p < 0.001). ⋯ Finally, the tolerance and safety profile of empagliflozin was good, with only a moderate increase in benign mycotic genital infections, a well-known adverse event with SGLT2 inhibitors. The remarkable effects of empagliflozin in the EMPA-REG OUTCOME trial, especially on mortality, should modify the management of patients with type 2 diabetes and a high cardiovascular risk in a near future.